Letters (Westmoreland)

Letter to the editor: McCormick OK with ketamine but not marijuana?

Tribune-Review
By Tribune-Review
2 Min Read Dec. 29, 2025 | 6 hours Ago
Go Ad-Free today

I’m gonna need someone to explain this to me like I’m 5. Help me please.

Pennsylvania has a medical cannabis market. Thousands of patients use the system annually to therapeutically manage chronic conditions. Pennsylvania took in nearly $87 million from gross receipt taxes in 2024 (not including any local taxes). Sen. Dave McCormick thinks cannabis shouldn’t be reclassified so that we can study it, but I wonder if he feels the same way about ketamine.

I’m asking because Elon Musk is a known, documented, self-avowed user of ketamine, and McCormick seemed to put up no fight or have nothing to say publicly about an immigrant drug user running a temporary government office (DOGE), and he definitely didn’t write a letter to the president about it.

I wonder why McCormick thinks it’s OK for a trillionaire with five-plus baby mamas to run a government organization while taking ketamine, but doesn’t think it’s OK for you to unwind with a gummy after you’ve been on your feet scanning groceries, trying to educate other people’s kids or answering constituent service lines for a political party complicit in the destruction of Americans’ safety nets like Medicaid, SNAP and the ACA.

Sen. McCormick, let’s be consistent. Who are the rules for? Why are we writing Dear Leader about rescheduling weed when we also full-throatedly pedestaled a ketamine-fueled bull to wreck USAID?

Billy King

San Francisco, Calif.

The writer is formerly of Dormont.

Share

Tags:

About the Writers

Push Notifications

Get news alerts first, right in your browser.

Enable Notifications

Content you may have missed

Enjoy TribLIVE, Uninterrupted.

Support our journalism and get an ad-free experience on all your devices.

  • TribLIVE AdFree Monthly

    • Unlimited ad-free articles
    • Pay just $4.99 for your first month
  • TribLIVE AdFree Annually BEST VALUE

    • Unlimited ad-free articles
    • Billed annually, $49.99 for the first year
    • Save 50% on your first year
Get Ad-Free Access Now View other subscription options